Nintedanib Clonmel Healthcare (Nintedanib)

The drug blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—preventing the signals that drive fibroblast growth, new blood‑vessel formation and excess matrix deposition. By interrupting these pathways, Nintedanib reduces the fibrotic remodeling that damages lung tissue.

The exact dose and dosing schedule are determined by the prescribing physician based on the patient’s condition, renal and hepatic function, and tolerance. Clinicians follow the product label and adjust as needed; patients should not change the dose without medical advice.

Safety data for Nintedanib during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should discuss alternatives with their doctor.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both aim to slow disease progression, Nintedanib targets a broader range of tyrosine kinases, which may offer different efficacy and safety profiles. Choice between them depends on individual patient factors, tolerability and physician judgment.

Nintedanib should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the product out of reach of children and avoid exposure to direct sunlight.

The medication is taken orally, usually as whole tablets with food to reduce gastrointestinal upset. Patients should swallow the tablet whole with a full glass of water and follow the dosing instructions provided by their healthcare professional.

Key serious risks include liver enzyme elevation, which requires regular monitoring; severe bleeding, especially when combined with anticoagulants; and rare but life‑threatening gastrointestinal perforation. Patients should report any signs of abdominal pain, jaundice, unusual bruising or bleeding promptly.

Nintedanib is contraindicated in patients with severe hepatic impairment, active bleeding disorders, or uncontrolled gastrointestinal ulcers. It should also be avoided in individuals taking strong CYP3A4 or P‑gp inhibitors without close supervision, and in patients with known hypersensitivity to the drug or its excipients.